The Role of the MAPK Signaling, Topoisomerase and Dietary Bioactives in Controlling Cancer Incidence (original) (raw)

Topoisomerase 2 Alpha and the Case for Individualized Breast Cancer Therapy

Maria Whelan

Annals of Surgical Oncology, 2010

View PDFchevron_right

P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas

Dijana Gugic Bokun

Diagnostic Pathology, 2013

View PDFchevron_right

MAPK inhibition by 1α,25(OH)2–Vitamin D3 in breast cancer cells

Ana Rosi

The Journal of Steroid Biochemistry and Molecular Biology, 2004

View PDFchevron_right

Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway

Paola Perego

Current Pharmaceutical Design, 2012

View PDFchevron_right

Interleukin-6 Is Required for Pancreatic Cancer Progression by Promoting MAPK Signaling Activation and Oxidative Stress Resistance

Ivy Chung

Cancer Research, 2013

View PDFchevron_right

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

Diana Brassard

Clinical Cancer Research, 2009

View PDFchevron_right

Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents

Giacomo Signorino

PLOS ONE, 2018

View PDFchevron_right

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Federico Rojo

2008

View PDFchevron_right

Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers

Charles Rajadurai

medRxiv (Cold Spring Harbor Laboratory), 2024

View PDFchevron_right

Changes of Topoisomerase II Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival

C. Natoli

Clinical Cancer Research, 2006

View PDFchevron_right

A Phase II Clinical Trial of Topotecan in Japanese Patients with Relapsed Ovarian Carcinoma

Keiichi Fujiwara

Japanese Journal of Clinical Oncology, 2010

View PDFchevron_right

Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells

Krzysztof Nieznanski

Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1995

View PDFchevron_right

Exploring DNA Topoisomerase I Ligand Space in Search of Novel Anticancer Agents

Laurence Wakelin

PLoS ONE, 2011

View PDFchevron_right

Phytochemicals and cancer chemoprevention

Journal of Cancer Metastasis and Treatment

Journal of Cancer Metastasis and Treatment, 2020

View PDFchevron_right

Cancer Prevention: Lessons Learned and Future Directions

Barbara Dunn

Trends in Cancer, 2016

View PDFchevron_right

The Mitogen-Activated Protein Kinase Kinase 4 Has a Pro-Oncogenic Role in Skin Cancer

Cathy Tournier

Cancer Research, 2010

View PDFchevron_right

Diet and Cancer Prevention: Where We Are, Where We Are Going

Carlos Hernando Murcia Gonzalez

Nutrition and Cancer, 2006

View PDFchevron_right

142. Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases

Kazuhiro KONDO

Biomedicine & Pharmacotherapy, 1992

View PDFchevron_right

Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature

manjeet kumar

Cancer Preventive and Therapeutic Compounds: Gift From Mother Nature, 2017

View PDFchevron_right

Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers

PABLO TAMAYO

Molecular Cancer Research, 2020

View PDFchevron_right

Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid

Susan Ceryak

Molecular Cancer Therapeutics, 2006

View PDFchevron_right

Recent progress in cancer therapeutics

Michael Rossbach

Translational oncology, 2009

View PDFchevron_right

Recent Progress in Cancer Research

Abdenbi Khalqallah

Association of Schools of Public Health, 1953

View PDFchevron_right

Cutting Edge Therapies for Cancer in the 21st Century

PARASKEVI V VOGIATZI

2014

View PDFchevron_right

Adenylate Kinase and Metabolic Signaling in Cancer Cells

Ljudmila Klepinina

Frontiers in Oncology, 2020

View PDFchevron_right

Tracking the cell cycle origins for escape from topotecan action by breast cancer cells

Paul Smith

British Journal of Cancer

View PDFchevron_right

Cancer research: On the offensive

Alison Abbott

Nature, 2002

View PDFchevron_right

Alpha, beta-unsaturated lactones 2-furanone and 2-pyrone induce cellular DNA damage, formation of topoisomerase I- and II-DNA complexes and cancer cell death

Santiago Mateos

Toxicology Letters, 2013

View PDFchevron_right

Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family

John Kehrl

Nature, 1996

View PDFchevron_right

Pathways connecting inflammation and cancer

Cecilia Garlanda

Current Opinion in Genetics & Development, 2008

View PDFchevron_right

Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?

David Gewirtz

Biochemical Pharmacology, 1991

View PDFchevron_right

Mitotic Arrest Induced by a Novel Family of DNA Topoisomerase II Inhibitors

Fernando garcia tellado

Journal of Medicinal Chemistry, 2010

View PDFchevron_right

Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma

Sijie Lin

Cellular Signalling, 2018

View PDFchevron_right

Application of Novel Molecular Biology in Cancer Therapy

asadollah asadi

Basic & Clinical Cancer Research, 2022

View PDFchevron_right

Keskin A. Impact of Polyphenolic Compounds on the MAPK Signaling Pathway against Carcinogenesis. J Clin Pract Res 2023; 45(3): 217–21.

Adem Keski̇n, Journal of Clinical Practice and Research

Journal of Clinical Practice and Research, 2023

View PDFchevron_right